Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
Cingulate Inc. Submits NDA for ADHD Treatment: Cingulate Inc. has submitted a New Drug Application (NDA) to the FDA for its lead product, CTx-1301, an innovative extended-release tablet formulation of dexmethylphenidate aimed at treating ADHD, promising fast onset and all-day efficacy.
Potential Market Impact and Technology: The company believes CTx-1301 could capture significant market share in the $23 billion U.S. ADHD market, leveraging its proprietary Precision Timed Release™ platform technology to enhance patient care and expand into other therapeutic areas.
Trade with 70% Backtested Accuracy
Analyst Views on CINGW
No data
About the author
Cingulate's Top ADHD Candidate CTx-1301 Chosen for Podium Presentation at AACAP Annual Meeting
CTx-1301 Presentation: Cingulate Inc. announced that data from its ADHD candidate CTx-1301 will be presented at the AACAP Annual Meeting, highlighting its once-daily, extended-release formulation aimed at improving treatment for ADHD patients.
Expert Presentation: Dr. Ann Childress, a leading ADHD specialist, will present the Phase 3 trial results, emphasizing CTx-1301's efficacy and safety in pediatric subjects with ADHD.
Innovative Drug Delivery: CTx-1301 utilizes Cingulate's Precision Timed Release™ platform to provide three timed releases of medication throughout the day, addressing limitations of current stimulant therapies.
Company Overview: Cingulate Inc. is focused on developing next-generation pharmaceutical products to enhance patient outcomes, with CTx-1301 in late-stage development for ADHD and other candidates targeting anxiety and neuropsychiatric conditions.
Cingulate Forms Exclusive Manufacturing Alliance with Bend Bio Sciences for Upcoming ADHD Treatment Commercialization
Commercial Supply Agreement: Cingulate Inc. has entered into a commercial supply agreement with Bend Bio Sciences for the manufacturing of CTx-1301, its lead ADHD treatment, ensuring exclusive manufacturing capabilities in the U.S. through 2028, pending FDA approval.
Innovative Drug Delivery: CTx-1301 utilizes Cingulate's proprietary Precision Timed Release™ (PTR™) technology to provide a novel, extended-release formulation of dexmethylphenidate, designed to improve ADHD treatment by delivering medication in a controlled manner throughout the day.